Diagnósticos da América S.A. (BOVESPA:DASA3) agreed to acquire Laboratório PATOLOGIA CLÃNICA DR. GERALDO LUSTOSA CABRAL LTDA in June 2022. Lustosa has BRL 49.6 million in revenue in 2021, The conclusion of this transaction is subject to compliance with certain condition precedents, including approval from the Brazilian Antitrust Authority (CADE).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.42 BRL | -3.66% | -19.91% | -64.45% |
05-16 | Transcript : Diagnósticos da América S.A., Q1 2024 Earnings Call, May 16, 2024 | |
05-15 | Diagnósticos da América S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.45% | 487M | |
+25.52% | 88.99B | |
-24.52% | 74.82B | |
-5.56% | 25.03B | |
+4.31% | 17.88B | |
-14.25% | 16.43B | |
+2.97% | 15.77B | |
+70.11% | 13.09B | |
+79.20% | 13.21B | |
+40.44% | 12.9B |
- Stock Market
- Equities
- DASA3 Stock
- News Diagnosticos da América S.A.
- Diagnósticos da América S.A. agreed to acquire Laboratório PATOLOGIA CLÍNICA DR. GERALDO LUSTOSA CABRAL LTDA.